E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic systolic heart failure |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008908 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this trial is to evaluate the efficacy and safety of eplerenone plus standard heart failure (HF) therapy versus placebo plus standard HF therapy on the cumulative incidence of cardiovascular (CV) mortality and HF hospitalisation (a composite primary endpoint). |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial: 1. Written informed consent obtained prior to the initiation of any study procedures 2. Male or female subjects, ≥ 60 years of age at the time informed consent is obtained 3. Chronic systolic heart failure (HF) of either ischaemic or non-ischaemic aetiology:
a. Duration: at least 4 weeks
b. Left ventricular ejection fraction (LVEF): ≤ 30% by echocardiography, contrast ventriculography, magnetic resonance imaging or nuclear imaging, based on local clinical practice. The most recent measurement within 6 months prior to randomisation must be used.
c. Functional Capacity: Currently NYHA II (in the investigator’s opinion)
d. Treatments (for ACE inhibitors, ARBs and b-blockers, optimal target or maximal tolerated dose unless contraindicated):
· Angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs)
· β-blocker
· Diuretic, if clinically indicated to reduce fluid retention
4. Serum potassium (K+) level ≤ 5.0mmol/L within 24 hours prior to randomisation
5. Estimated glomerular filtration rate (eGFR) >30 ml/min/1.73m2 within 24 hours prior to randomisation.
6. Randomisation must occur no later than 90 days from the date of admission for index cardiovascular (CV) hospitalisation. (If clinically stable, the subject may be randomised during this index cardiovascular (CV) hospitalisation.)
7. If the subject is a female of childbearing potential, she must:
a. Have a negative serum pregnancy within 72 hours prior to the first dose of study drug AND b. Agree to use an adequate form of contraception (Abstinence will not be considered an acceptable form of contraception.) |
|
E.4 | Principal exclusion criteria |
Subjects presenting with any of the following will not be included in the trial:
1. Patients with severe chronic systolic heart failure, defined as patients who demonstrate symptoms usually at rest despite optimal medical therapy
2. Patients with a myocardial infarction complicated by left ventricular systolic dysfunction and clinical heart failure within 30 days prior to randomisation
3. Patients with stroke within 30 days prior to randomisation
4. Patients who have had cardiac surgery within 30 days prior to randomisation
5. Patients who have had percutaneous coronary intervention (PCI) within 30 days prior to randomisation
6. Patients, who in the opinion of the investigator, require treatment with eplerenone, spironolactone or potassium canrenoate
7. Patients with uncontrolled hypertension, defined as having a systolic blood pressure ≥ 180 mmHg and/or a diastolic blood pressure ≥ 110 mmHg
8. Patients with symptomatic hypotension or having a systolic blood pressure ≤ 85 mmHg
9. Patients, who in the opinion of the investigator, require treatment with potassium-sparing diuretics or potassium supplements
10. History of hypersensitivity to eplerenone or spironolactone
11. Evidence of cardiogenic shock
12. Patients in whom the primary cause of heart failure is valve disease, pericardial disease or an obstructive or restrictive cardiomyopathy .
13. Intra-aortic balloon pump or other mechanical assist device
14. Patients awaiting cardiac transplantation
15. Serum potassium > 5.0 mmol/L within 24 hours prior to randomisation
16. Estimated glomerular filtration rate (eGFR) ≤30 ml/min/1.73m2 within 24 hours prior to randomisation.
17. Concomitant use of potent cytochrome p450 3A4 (CYP3A4) inhibitors, such as but not limited to: a. Ketoconazole b. Itraconazole c. Nefazodone d. Troleandomycin e. Clarithromycin f. Ritonavir g. Nelfinavir
18. Concomitant use of cytochrome p450 3A4 (CYP3A4) inducers, such as but not limited to: a. St. John’s Wort b. Rifampin c. Carbamazepine d. Phenytoin e. Phenobarbitol
19. Hemoglobin <10g/dL
20. Patients with preexisting significant hepatic disease (for example, known positive serology for viral hepatitis) or aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3 times the upper limits of normal
21. Patients status-post gastric bypass surgery, partial gastrectomy or other surgery of the gastrointestinal tract that may interfere with the absorption of eplerenone |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is the first occurrence of cardiovascular (CV) mortality and heart failure (HF) hospitalisation.
Cardiovascular (CV) mortality is defined as death due to: Heart Failure Myocardial infarction Cardiac arrhythmia Stroke/cerebral vascular accident (CVA) or transient ischaemic attack (TIA) Other CV cause (e.g., aneurysm or pulmonary embolism)
Hospitalisation for HF |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 0 |